MOMENTA PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2004 Stock Incentive Plan, as amendedRestricted Stock Agreement • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made on August 22, 2006 between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Craig Wheeler (the “Participant”).
Novartis Pharma AG AND Momenta Pharmaceuticals, Inc. INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of July 25, 2006, by and between Novartis Pharma AG (the “Investor”), a corporation organized under the laws of Switzerland, with its principal place of business at Lichtstraße 35, CH 4058 Basel BS, and Momenta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts 02142.
Novartis Pharma AG AND Momenta Pharmaceuticals, Inc. STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of July 25, 2006, by and between Novartis Pharma AG (the “Investor”), a corporation organized under the laws of Switzerland, with its principal place of business at Lichtstraße 35, CH 4058 Basel BS, and Momenta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts 02142.
MOMENTA PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2004 Stock Incentive PlanRestricted Stock Agreement • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made on March 7, 2006 between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Ganesh Venkataraman (the “Participant”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. THIRD AMENDMENT TO THE OCTOBER 31, 2002 LICENSEMomenta Pharmaceuticals Inc • November 8th, 2006 • Biological products, (no disgnostic substances)
This Third Amendment, effective as of the date set forth above the signatures of the parties below, pertains to the Exclusive Patent License Agreement, effective on October 31, 2002, as subsequently amended by a First Amendment on November 15, 2002 and a Second Amendment on July 17, 2004, by and between the Massachusetts Institute of Technology (“M.I.T.”) and Momenta Pharmaceuticals, Inc. (“COMPANY”).
Momenta Pharmaceuticals, Inc. Nonstatutory Stock Option Agreement Granted Under 2004 Stock Incentive Plan, as amendedNonstatutory Stock Option Agreement • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances)
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. FIFTH AMENDMENT TO THE NOVEMBER 1, 2002 LICENSEMomenta Pharmaceuticals Inc • November 8th, 2006 • Biological products, (no disgnostic substances)
This Fifth Amendment, effective as of the date set forth above the signatures of the parties below, pertains to the Amended and Restated Exclusive Patent License Agreement, effective on November 1, 2002, as subsequently amended by a First Amendment on November 15, 2002, a Letter Agreement on September 12, 2003, a Letter Agreement on October 22, 2003, a Second Amendment on November 19, 2003, a Third Amendment on April 2, 2004, and a Fourth Amendment on July 17, 2004, by and between the Massachusetts Institute of Technology (“M.I.T.”) and Momenta Pharmaceuticals, Inc. (“COMPANY’)
SUBLEASESublease • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Sublease (the “Sublease”) is made as of September 8, 2006 by and between Archemix Corp., a Delaware corporation, having an address of 300 Third Street, Cambridge, Massachusetts 02142 (“Sublandlord”) and Momenta Pharmaceuticals, Inc., a Delaware corporation, having an address of 675 West Kendall Street, Cambridge, MA 02142 (“Subtenant”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. Momenta Pharmaceuticals, Inc.Momenta Pharmaceuticals Inc • November 8th, 2006 • Biological products, (no disgnostic substances)
This letter is in reference to the Amended and Restated Exclusive Patent License Agreement by and between Massachusetts Institute of Technology (“MIT”) and Momenta Pharmaceuticals, Inc. (“Momenta”) dated as of November 1, 2002 and as amended by a First Amendment dated November 1, 2002, letter agreements dated September 12, 2003 and October 22, 2003, a Second Amendment dated November 19, 2003, a Third Amendment dated April 2, 2004, a Fourth Amendment dated July 17, 2004, a Fifth Amendment dated August 5, 2006 and a letter Agreement dated August 10, 2006 (collectively, the “MIT-Momenta Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings given such terms in the MIT-Momenta Agreement.
Momenta Pharmaceuticals, Inc. Incentive Stock Option Agreement Granted Under 2004 Stock Incentive Plan, as amendedIncentive Stock Option Agreement • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances)
EMPLOYMENT AGREEMENTEmployment Agreement • November 8th, 2006 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS EMPLOYMENT AGREEMENT (the “Agreement”), made this 22nd day of August 2006, is entered into by Momenta Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts (the “Company”), and Craig Wheeler, residing at 3 Valley View Lane, Orinda, California 94563 (the “Employee”).
